Research ArticleTAUOPATHIES

Anti-tau antibody administration increases plasma tau in transgenic mice and patients with tauopathy

See allHide authors and affiliations

Science Translational Medicine  19 Apr 2017:
Vol. 9, Issue 386, eaal2029
DOI: 10.1126/scitranslmed.aal2029

You are currently viewing the editor's summary.

View Full Text

Log in to view the full text

Log in through your institution

Log in through your institution

Tracking tau in mice and humans

Tauopathies, such as progressive supranuclear palsy and Alzheimer’s disease, are a group of neurodegenerative diseases characterized by the accumulation of aggregated forms of tau protein in the brain. Administration of anti-tau antibodies is a new treatment approach being tested for these diseases. Tau is present at high levels in the brain and low levels in the plasma. Peripheral administration of an anti-tau antibody markedly increased tau in the plasma of both transgenic mice expressing human tau and patients with tauopathy (Yanamandra et al.). The increase in plasma tau in mice correlated with an increase in brain extracellular and soluble tau.